Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... REDWOOD CITY, Calif. , May 22, 2015 /PRNewswire/ ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today announced that interim chief executive officer ... 2015 Healthcare Conference and chief financial officer Tim ... Science Conference. Details of the two presentations are as ...
(Date:5/21/2015)... Research and Markets ( ... "North American Active Wound Care Market by ... & Ulcer), by End-User (In-Patient, & Out-Paient) - ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North ... grow at a CAGR of 3.1% from 2014 ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: ... employee Greg Watson , the company,s vice president of ... the company,s common stock, at a per share exercise price ... The stock option was granted pursuant to Cardica, Inc.,s Inducement ... in May 2015 under Rule 5653(c)(4) of the Nasdaq Global ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2
... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a ... products for the treatment of central nervous system disorders, ... quarter ended March 31, 2012. Key Highlights: ... continues to advance towards the goal of a projected ...
... Inc. (Nasdaq: REGN ) and Bayer ... Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen Pharmaceutical Co., ... Injection in Japan.  As previously announced, Bayer Yakuhin ... the Ministry of Health, Labor and Welfare (MHLW) ...
Cached Medicine Technology:Vanda Pharmaceuticals Reports First Quarter 2012 Results 2Vanda Pharmaceuticals Reports First Quarter 2012 Results 3Vanda Pharmaceuticals Reports First Quarter 2012 Results 4Vanda Pharmaceuticals Reports First Quarter 2012 Results 5Vanda Pharmaceuticals Reports First Quarter 2012 Results 6Vanda Pharmaceuticals Reports First Quarter 2012 Results 7Vanda Pharmaceuticals Reports First Quarter 2012 Results 8Vanda Pharmaceuticals Reports First Quarter 2012 Results 9Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 2Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 3Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 4Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 5Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 6Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 7
(Date:5/25/2015)... 2015 A recent report for Mass ... have died as a direct result of an opiate overdose ... 33% rise in overdose deaths attributed to prescription opiate medications, ... doesn’t care about geography. This issue doesn’t care about race. ... about class.” As the state of Mass. reels from the ...
(Date:5/25/2015)... Aliso Viejo, CA (PRWEB) May 25, 2015 ... generate their very own VJ neon light backdrops with a click ... camera position, scale and much more all within Final Cut Pro ... ranging from categories such as drop zones, kaleidoscope and much more ... ProDrop Light Show drop zones and text presets, users ...
(Date:5/25/2015)... Tunstall Americas announces major investment in ... of service to its Medical Answering Service customers. ... of resources, Tunstall now provides a seamless transition between ... Service to ensure superior patient satisfaction. , ... over $10 million in expanded facilities and the latest ...
(Date:5/24/2015)... May 25, 2015 Pacific Prime has announced that ... report looking at the cost of individual international health insurance. ... 2 looks at the cost of health insurance in six top ... on, Hong Kong , Singapore ... the UAE , the UK , Article ...
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4
... ... April 13, 2009 -- Accept an illicit injection and the result ... Coalition for Injectable Safety. The recent death of a Bronx, NY ... her thighs and buttocks is an unfortunate and repeating pattern of incidents ...
... NEW YORK, April 13 When the going gets tough, ... stands to reason that Equinox Fitness Clubs is still going ... Equinox opens its second Boston location at 225 Franklin Street. ... the heart of Boston,s financial district. "After making a ...
... Proven Principles of Movement and Supportive Atmosphere to Achieve ... announced the launch of The Momentum Walk-It Challenge, encouraging ... physical activity into their lives. Between April 12 ... will be able to join The Momentum Walk-It Challenge. ...
... , , MONDAY, April 13 (HealthDay News) -- Race and genetics may ... long suspected, a new study finds. , Though racial disparities ... less apparent when zeroing in on smaller populations or geographical areas, ... report in the May 15 issue of Cancer suggests ...
... April 13 Accuray Incorporated (Nasdaq: ARAY ), ... that it will report results for its third quarter fiscal ... 2009 after the market closes.A conference call to review the ... and will be hosted by Euan S. Thomson, Ph.D., president ...
... all eyes turn to the health reform debate in Washington, Bruce ... - will urge that "everything be on the table" at ... Mr. Bodaken will participate in a keynote panel kicking off the ... with an address by Dora Hughes, counselor to the Secretary of ...
Cached Medicine News:Health News:Consumer Alert: Illegal Silicone Injections Result in Death 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 3Health News:Consumer Alert: Illegal Silicone Injections Result in Death 4Health News:Equinox Fitness Clubs Continues National Expansion with the Opening of its Second Boston Location 2Health News:Equinox Fitness Clubs Continues National Expansion with the Opening of its Second Boston Location 3Health News:Weight Watchers(R) Kicks Off Spring by Urging People to Get Moving With 'The Momentum(TM) Walk-It Challenge' 2Health News:Weight Watchers(R) Kicks Off Spring by Urging People to Get Moving With 'The Momentum(TM) Walk-It Challenge' 3Health News:Race May Not Be Key in Cancer Disparities 2Health News:Accuray Incorporated to Report Financial Results for Third Quarter Fiscal Year 2009 2Health News:Blue Shield of California CEO to Speak at World Health Care Congress in Washington D.C. 2
Micro Dissecting Curette, 5 1/2", Round....
14 cm, very delicate, round cupped jaws, straight jaws, 3.0 mm...
Wilson pituitary forcep, flattened tip, 3 mm bite, 145 mm effective....
Bayonet Pituitary Rongeur, ceramic, 9 length 165 mm, 6.5 working length....
Medicine Products: